SYNIMMUNE GmbH is a biotechnology company focusing on the development of novel mono- and bispecific antibodies for improved immunotherapy of orphan hematopoietic malignancies.
The company was founded in 2010 as a spin-off of the Department of Immunology at the University of Tübingen, which is headed by Prof. Dr. Hans-Georg Rammensee. Synimmune was awarded in two rounds of the funding program "Gründungsoffensive-Biotechnologie" (GO-Bio) from the Federal Ministry of Education and Research (BMBF).
Our goal is to enhance the therapeutic efficacy of antibody treatment by improving the selective activation of immune effector cells, and to bridge the “translational gap” between conception and clinical evaluation as fast as possible.
SYNIMMUNE GmbH holds a manufacturing authorization for the production of therapeutic antibodies and works in close co-operation with the University Hospital in Tübingen, Germany.
12. January 2017 - The Paul-Ehrlich-Institute (PEI) authorises SYNIMMUNE GmbH to start its "First-in-Man-study to evaluate the safety, tolerability and preliminary efficacy of the Fc-optimized FLT3 antibody FLYSYN for the treatment of acute myeloid leukemia patients with minimal residual disease".